251 related articles for article (PubMed ID: 37443031)
1. CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes.
Quadri M; Tiso N; Musmeci F; Morasso MI; Brooks SR; Bonetti LR; Panini R; Lotti R; Marconi A; Pincelli C; Palazzo E
J Exp Clin Cancer Res; 2023 Jul; 42(1):167. PubMed ID: 37443031
[TBL] [Abstract][Full Text] [Related]
2. Do DLX3 and CD271 Protect Human Keratinocytes from Squamous Tumor Development?
Palazzo E; Marconi A; Pincelli C; Morasso MI
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31331058
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
4. CD271 Down-Regulation Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in Zebrafish.
Saltari A; Truzzi F; Quadri M; Lotti R; Palazzo E; Grisendi G; Tiso N; Marconi A; Pincelli C
J Invest Dermatol; 2016 Oct; 136(10):2049-2058. PubMed ID: 27328305
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation.
Zhou K; Wu C; Cheng W; Zhang B; Wei R; Cheng D; Li Y; Cao Y; Zhang W; Yao Z; Zhang X
Cell Death Dis; 2024 Apr; 15(4):252. PubMed ID: 38589352
[TBL] [Abstract][Full Text] [Related]
6. EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma.
Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Toriseva M; Kivisaari A; Ala-Aho R; Kallajoki M; Veräjänkorva E; Honkanen HK; Heljasvaara R; Pihlajaniemi T; Grénman R; Peltonen J; Peltonen S; Kähäri VM
J Invest Dermatol; 2015 Jul; 135(7):1882-1892. PubMed ID: 25789706
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-203 Inversely Correlates with Differentiation Grade, Targets c-MYC, and Functions as a Tumor Suppressor in cSCC.
Lohcharoenkal W; Harada M; Lovén J; Meisgen F; Landén NX; Zhang L; Lapins J; Mahapatra KD; Shi H; Nissinen L; Kähäri VM; Ståhle M; Sonkoly E; Grandér D; Arsenian-Henriksson M; Pivarcsi A
J Invest Dermatol; 2016 Dec; 136(12):2485-2494. PubMed ID: 27452220
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.
Piipponen M; Nissinen L; Farshchian M; Riihilä P; Kivisaari A; Kallajoki M; Peltonen J; Peltonen S; Kähäri VM
J Invest Dermatol; 2016 Aug; 136(8):1701-1710. PubMed ID: 27049681
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of LINC00319 indicates a poor prognosis and promotes cell proliferation and invasion in cutaneous squamous cell carcinoma.
Li F; Liao J; Duan X; He Y; Liao Y
J Cell Biochem; 2018 Dec; 119(12):10393-10405. PubMed ID: 30145798
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA PICSAR knockdown inhibits the progression of cutaneous squamous cell carcinoma by regulating miR-125b/YAP1 axis.
Lu X; Gan Q; Gan C; Zheng Y; Cai B; Li X; Li D; Yin G
Life Sci; 2021 Jun; 274():118303. PubMed ID: 32841663
[TBL] [Abstract][Full Text] [Related]
11. GRIM-19 represses the proliferation and invasion of cutaneous squamous cell carcinoma cells associated with downregulation of STAT3 signaling.
Wu N; Hui H; Cui L; Yang F
Biomed Pharmacother; 2017 Nov; 95():1169-1176. PubMed ID: 28926927
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SCARNA2 induces cutaneous squamous cell carcinoma progression via modulating miR-342-3p expression.
Zhang Z; Jia M; Wen C; He A; Ma Z
J Gene Med; 2020 Dec; 22(12):e3242. PubMed ID: 32558970
[TBL] [Abstract][Full Text] [Related]
13. CircRNA hsa_circ_0070934 functions as a competitive endogenous RNA to regulate HOXB7 expression by sponging miR‑1236‑3p in cutaneous squamous cell carcinoma.
Zhang DW; Wu HY; Zhu CR; Wu DD
Int J Oncol; 2020 Aug; 57(2):478-487. PubMed ID: 32626939
[TBL] [Abstract][Full Text] [Related]
14. UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines.
Chen IP; Bender M; Spassova I; Henning S; Kubat L; Fan K; Degenhardt S; Mhamdi-Ghodbani M; Sriram A; Volkmer B; Boukamp P; Becker JC; Greinert R
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3215-3231. PubMed ID: 32865618
[TBL] [Abstract][Full Text] [Related]
15. Proline-rich 11 (PRR11) promotes the progression of cutaneous squamous cell carcinoma by activating the EGFR signaling pathway.
Wang S; Zhang X; Lei H; Song L; Huang Y; Kang T; Zhang M; Wang N; Yang P; Feng S; Wang J; Bai R; Wang N; Wang W; Zheng Y
Mol Carcinog; 2023 May; 62(5):613-627. PubMed ID: 36727626
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-664 functions as an oncogene in cutaneous squamous cell carcinomas (cSCC) via suppressing interferon regulatory factor 2.
Li X; Zhou C; Zhang C; Xie X; Zhou Z; Zhou M; Chen L; Ding Z
J Dermatol Sci; 2019 Jun; 94(3):330-338. PubMed ID: 31138473
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the interplay between senescent dermal fibroblasts and cutaneous squamous cell carcinoma cell lines at different stages of tumorigenesis.
Toutfaire M; Dumortier E; Fattaccioli A; Van Steenbrugge M; Proby CM; Debacq-Chainiaux F
Int J Biochem Cell Biol; 2018 May; 98():113-126. PubMed ID: 29550586
[TBL] [Abstract][Full Text] [Related]
18. lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.
Zou S; Gao Y; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195851
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.
Olasz EB; Seline LN; Schock AM; Duncan NE; Lopez A; Lazar J; Flister MJ; Lu Y; Liu P; Sokumbi O; Harwood CA; Proby CM; Neuburg M; Lazarova Z
PLoS One; 2015; 10(5):e0125412. PubMed ID: 25938461
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.
Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Piipponen M; Kivisaari A; Kallajoki M; Grénman R; Peltonen J; Peltonen S; Quint KD; Bavinck JNB; Kähäri VM
Oncotarget; 2017 Jul; 8(28):45825-45836. PubMed ID: 28526809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
